{"title":"Metabolically Silent Diffuse Hepatic Involvement in Multiple Myeloma: An <sup>18</sup>F-FDG-PET/CT Pitfall.","authors":"Seçkin Bilgiç, Merve Okuyan, Efrah İbrahim","doi":"10.4274/mirt.galenos.2026.09475","DOIUrl":null,"url":null,"abstract":"<p><p>Diffuse hepatic involvement in multiple myeloma is rare and may present a diagnostic challenge <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT). We present the case of a 59-year-old man with a 3-year history of multiple myeloma who developed progressive hepatomegaly and perihepatic ascites. <sup>18</sup>F-FDG PET/CT demonstrated marked diffuse liver enlargement without any focal or diffuse hepatic 18F-FDG uptake, while mild diffuse skeletal uptake suggested a globally <sup>18</sup>F-FDG-low myeloma phenotype. Given the discordance between severe morphological findings and the absence of hepatic metabolic activity, a liver biopsy was performed, which revealed diffuse sinusoidal infiltration by CD138-positive, lambda-restricted plasma cells and excluded hepatic amyloidosis. Following systemic therapy, hepatomegaly and ascites regressed, while hepatic <sup>18</sup>F-FDG uptake remained absent. Written informed consent for publication was obtained from the patient. This case highlights an important limitation of <sup>18</sup>F-FDG PET/CT in detecting diffuse hepatic myeloma and emphasizes the need for multimodal diagnostic integration.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":" ","pages":"137-141"},"PeriodicalIF":0.9000,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13235832/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2026.09475","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Diffuse hepatic involvement in multiple myeloma is rare and may present a diagnostic challenge 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). We present the case of a 59-year-old man with a 3-year history of multiple myeloma who developed progressive hepatomegaly and perihepatic ascites. 18F-FDG PET/CT demonstrated marked diffuse liver enlargement without any focal or diffuse hepatic 18F-FDG uptake, while mild diffuse skeletal uptake suggested a globally 18F-FDG-low myeloma phenotype. Given the discordance between severe morphological findings and the absence of hepatic metabolic activity, a liver biopsy was performed, which revealed diffuse sinusoidal infiltration by CD138-positive, lambda-restricted plasma cells and excluded hepatic amyloidosis. Following systemic therapy, hepatomegaly and ascites regressed, while hepatic 18F-FDG uptake remained absent. Written informed consent for publication was obtained from the patient. This case highlights an important limitation of 18F-FDG PET/CT in detecting diffuse hepatic myeloma and emphasizes the need for multimodal diagnostic integration.
期刊介绍:
Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.